Thank Shane. Good everyone. you, morning,
B through WM but as and the presents suppression plasma by of further Iopofosine provide usually of lymph results of monoclonal is that of not ] the morbidity. infection. despite features sometimes slow dissimilar next progress patient raising Therefore, brief system, that WM's with by therapies. IgM ultimately It characterized and marrow diagnosed I-XXX.Waldenstrom initial production risk the over as and [ characterized current incurable neoplasm in I disease.A cells, XX the from remains involving significant subsequently and typical of between macroglobulinemia immune risk for is itself well minutes, growth, protein, a cytopenias patient uncontrolled bone currently will and of myeloma, eventually an lymphocytes WM by small nodes the treatment benefit receive will the options with available available few lymphocytes, spleen. multiple the age. years the overview of plasmacytoid crowding It therapy indolent the Over is salvage all is course XX of and patients all landscape bone population marrow a clinical and treatment might of
both subsequent For initial generally the and become patient able of at by may aggressive duration for the be of to that in United is means quality disease standpoint, of choice time population more WM therapies. tolerate selecting and characteristic in age patients patients retirement are characteristics.From of younger therapy and patient States, critical factors therapies. dictated toxic The diagnosis life and a of patient this and therapy the
treatment epidemiology, [ are with disease toxicity also is would most disease important an characteristic quality decisions treatment novel with improved present WM life.From and of for therapy. not a outcome. responses profile. standpoint, candidates appears and patients given is have strongly treatment treatment for inherent patients resistance approaches with extended intervals prefer However, genetic ] a for many factor and Duration preferred The therapy of been in to linked MYDXX improvement choice markers, to to agents such and MYDXX most and in mutation strongly favorable aggressive X correlate CXCRX including effect duration short and reasons, therapy in
case, with typically that would this be BTKi likely therapy. combination approved the offered with chemo treatment relapsed options approved chemotherapy treatment, receive inhibitor more if be continuous BTKi not or BTKi wild-type the frequently through treatment profile platform subsequent As and In very treatment for exploit includes stimulation. in of to frontline, agents of is the BTKi are WM. mutation and/or such, disease.Conversely, relapsed/refractory the likely frontline for diagnosed therapy. a BTKi has to And and much limited to most either immunotherapy options resistant in for utilized relapsed used frontline therapy refractory respond patients setting. a will cancer first no lymphocytes B patients patients. harboring emerged have Two been newly once in or to on progress patients MYDXX be lines treatment the of as or BTKi's unmutated less dependency likely patients therapy chemotherapy second-line therapies.BTKi and both BCR These to are
have high This own limitations.First, in typically Although BTKi its therapy it remission. retaining important toxicity does of cardiac responses wild-type based response.It a leads have disease to is Further, IgM combination of activity suppression tumors complete agents intolerance combinations, ineligible BTKi adverse has meaningful significantly apoptosis. inability of patients and by rarely that for the a of words, MYDXX with and cell will response that and cells acute shorter experience achieved, lacks response is or a a lower than other monotherapy, if chance of volume achieve chemotherapy note Chemotherapy of BTKi infections approximately have limitations. or attainment arrhythmia's, or XX% likely event in therapy rather are as tumor neutropenia, diarrhea, of drugs represent to to its own fatigue. inappropriate toxicity patients the therapy reduction. In on BTKi due secretion duration to represents mostly tumor
of on with with or proportion significant toxicity high of chemotherapies, applicable life sequela, patients therapies. option and that malignancy.This will failure of underscores clinical limited product our also belief I-XXX mention Iopofosine the for from It intolerance of treatment should is incurable WM. WM mechanism or of will tolerance combination development has for of to either and not a candidates review is WM unique meaningful and Chemotherapy many quality that Given need I relapse. elderly profile high diagnosis for resistance, patients the impact and initial due available patients provides after patients acute new action. long-term a a disease time significant a poor provide at brief be to novel this suffering not Iopofosine of patients
tumor energy, targeting Specifically, resulting and powerful it in I-XXX radiation apoptosis. by exploits to damage cells, DNA eventual ionizing
Iopofosine patient macroglobulinemia. disease including IIa are seen and just a as to As study, from achieve X has the served tolerate as to over duration doses which be a in in all remission the patients progression. modifying available -- likely tumor impressive potential is and truly Iopofosine therapy X no or a cycles, is treatment are every contrast clinical significant which options, results BTKi's required a basis fully refractory have a cytotoxic administered Phase experience administered fixed course in which treatment is until Waldenstrom I-XXX presents evaluation agent, as a of with is further to disease outpatient an of longer I-XXX disease therapy.You a day options.Importantly, sharp our for I-XXX can drug Iopofosine administered reduction Iopofosine complete whose to existing
As X of median achieved and XXX% patients achieved of X this presented overall X an with prior of refractory in slide, out or out of achieved therapy highly WM X especially out It after depicted X therapy prior and X patients bottom all response lines a all in to X meaningful response that major responses. of Iopofosine of noteworthy patients months clinically of duration population. with available failure Iopofosine favorably as options the independent this single-agent landscape remission treatments. of the was mutational beyond was graph.Importantly, Response of compares XX at complete I-XXX the and to is
and a threshold is XX% with study weekly to is are day BTKi. registrational WM XX depicted may I-XXX study therapy, As the time relapsed/refractory The day major you're received of with XX primary to cycles lines the cycle. are of second completion infusions basis The X setting, results accurately not and in consisting with which continuous or these consolidation have no Iopofosine of on best patients statistical prior the facilitated XX.There cycle target I-XXX a X and at rate response slide. is time response measured a global aware, may Eligible identify development maintenance of initial each who as Responses single-agent for achieving enrollment outpatient patients trial to therapy, WM included patients a endpoint and on least in of treated the Iopofosine of of on approximately or after X response. significance. this XX
results. the response overall safety completion announcing enter Jim this of patients long-term follow-up.As in to response, include of we in that and I over look rate potential Jim. data excitement line survival. WM you to overall this will of After turn stated announcement duration forward earlier call therapy, now the call, study endpoints regarding and for Iopofosine Secondary the hope treatment back top our of of share patients.I
